Director's Affiliated Fund Makes $24.8M Investment in Mirum Pharmaceuticals
MIRM has more than doubled off its 52-week low of $36.88.
Summary
A director's affiliated fund, Frazier Life Sciences X, L.P., significantly increased its stake in Mirum Pharmaceuticals through a substantial open market purchase and shares acquired in connection with the recent Bluejay Therapeutics merger.
Key Events · Ownership and Investor Activity · MIRM
-
Significant Insider-Affiliated Investment
Patrick J. Heron, a Director, reported that Frazier Life Sciences X, L.P., an entity he is affiliated with, acquired $24,811,412 worth of Mirum Pharmaceuticals common stock.
-
Open Market Purchase
The acquisition included an open market purchase of 131,425 shares valued at $8,999,984.
-
Merger-Related Share Acquisition
An additional 159,277 shares, valued at $15,811,428, were acquired in connection with the merger of Bluejay Therapeutics, Inc. into Mirum Pharmaceuticals.
-
Follows Recent Acquisition
This insider activity follows the company's completion of the Bluejay Therapeutics acquisition, announced via an 8-K on January 26, 2026.
Analysis · MIRM · Life Sciences
Patrick J. Heron, a Director of Mirum Pharmaceuticals, reported that Frazier Life Sciences X, L.P., an entity with which he is affiliated, acquired a total of $24.8 million in company stock. This includes an open market purchase of nearly $9 million and an additional acquisition of over $15.8 million in shares related to the recent merger with Bluejay Therapeutics. This substantial investment by an insider-affiliated entity, particularly following the completion of a significant acquisition, signals strong confidence in the company's strategic direction and future prospects. The transactions occurred on January 23, 2026, just days before the 8-K announcing the Bluejay acquisition completion on January 26, 2026, and while the stock is trading near its 52-week high.
At the time of this filing, MIRM was trading at $99.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1B. The 52-week trading range was $36.88 to $99.44. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.